{
  "abstract": "Background: In the Phase 3 DeLLphi-304 trial, tarlatamab significantly improved overall survival (OS) over chemotherapy for small-cell lung cancer (SCLC) progressed after platinum-based chemotherapy. We report efficacy and safety in the Japanese subpopulation.\n\nMethods: Patients were randomized to tarlatamab or amrubicin in Japan. The primary endpoint was OS. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and safety.\n\nResults: As of 29 Jan 2025 (data cutoff), 35 patients (tarlatamab, n = 12; amrubicin, n = 23) were enrolled. Baseline characteristics were generally balanced although fewer tarlatamab-treated patients had chemotherapy-free interval < 90 days or brain metastases. Median OS was NE (95% CI, 10.4, NE) for tarlatamab versus 11.5 (6.2, NE) months for amrubicin (HR [95% CI] = 0.533 [0.186, 1.529]). Twelve-month survival was 66.7% (33.7, 86.0) versus 47.0% (25.7, 65.6), respectively. Median PFS was 4.0 (1.3, 11.3) months versus 4.2 (2.1, 5.4) months (HR [95% CI] = 0.726 [0.339, 1.554]). ORR was 33.3% (9.9, 65.1) versus 26.1% (10.2, 48.4). Median DOR was 10.1 (3.0, NE) months versus 5.6 (2.8, NE) months. Grade ≥ 3 treatment-related adverse events were less frequent with tarlatamab (8.3%) versus amrubicin (56.5%). Cytokine release syndrome occurred in 75% of tarlatamab-treated patients (all were grade 1 or 2) and grade 2 immune effector cell-associated neurotoxicity syndrome was reported in 1 (8.3%) patient.\n\nConclusion: Tarlatamab demonstrated numerically longer OS and DOR, and higher ORR versus amrubicin in Japanese patients with SCLC, with fewer high-grade treatment-related adverse events. These results in Japanese patients support those of the global population.\n\nSupplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10147-026-03192-y.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Thoracic Oncology, Kansai Medical University Hospital, 2-3-1 Shin-machi, Hirakata city, Osaka 573-1191 Japan",
    "Sendai Kousei Hospital, Miyagi, Japan",
    "Internal Medicine III, Wakayama Medical University Hospital, Wakayama, Japan",
    "Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan",
    "Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan",
    "Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan",
    "Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan",
    "Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan",
    "Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan",
    "Department of Thoracic Oncology, Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama, Japan",
    "Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan",
    "Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan",
    "Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan",
    "Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan",
    "Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan",
    "Department of Respiratory Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan",
    "Amgen Inc, Thousand Oaks, CA USA",
    "Amgen K.K, Tokyo, Japan",
    "Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 20,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Takayasu Kurata",
      "orcid": "0000-0003-4123-3567"
    },
    {
      "affs": [
        1
      ],
      "name": "Shunichi Sugawara"
    },
    {
      "affs": [
        2
      ],
      "name": "Hiroaki Akamatsu"
    },
    {
      "affs": [
        3
      ],
      "name": "Kazushige Wakuda"
    },
    {
      "affs": [
        4
      ],
      "name": "Koichi Azuma"
    },
    {
      "affs": [
        5
      ],
      "name": "Takayuki Takahama"
    },
    {
      "affs": [
        6
      ],
      "name": "Hiroshi Kagamu"
    },
    {
      "affs": [
        7
      ],
      "name": "Hiroshi Yokouchi"
    },
    {
      "affs": [
        8
      ],
      "name": "Miyako Satouchi"
    },
    {
      "affs": [
        9
      ],
      "name": "Shuji Murakami"
    },
    {
      "affs": [
        10
      ],
      "name": "Kadoaki Ohashi"
    },
    {
      "affs": [
        11
      ],
      "name": "Makoto Nishio"
    },
    {
      "affs": [
        12
      ],
      "name": "Kazumi Nishino"
    },
    {
      "affs": [
        13
      ],
      "name": "Hiroki Izumi"
    },
    {
      "affs": [
        14
      ],
      "name": "Hiroshi Tanaka"
    },
    {
      "affs": [
        15
      ],
      "name": "Taichi Miyawaki"
    },
    {
      "affs": [
        16
      ],
      "name": "Shuang Huang"
    },
    {
      "affs": [
        16
      ],
      "name": "Upen Patil"
    },
    {
      "affs": [
        17
      ],
      "name": "Jihyun Park"
    },
    {
      "affs": [
        18
      ],
      "name": "Tatsuya Yoshida"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7rc5pwxaq52qq.bib",
  "cited_by": 0,
  "doi": "10.1007/s10147-026-03192-y",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13710598/",
  "id": "7rc5pwxaq52qq",
  "issns": [
    "1341-9625",
    "1437-7772"
  ],
  "landing_url": "https://doi.org/10.1007/s10147-026-03192-y",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2730|Lung Cancer Research Studies"
    ]
  ],
  "openalex": "W7213627913",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s10147-026-03192-y.pdf",
  "pmcid": "PMC13710598",
  "pmid": "42762420",
  "published": "2026-09-19",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/7rc5pwxaq52qq.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:21:32Z",
      "native_id": "PMC13710598",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s10147-026-03192-y"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Lung Cancer Research Studies",
      "subfield": "oncology"
    }
  ],
  "title": "Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study",
  "title_text": "Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T12:21:32Z",
  "url": "https://research.draconitic.com/paper/7rc5pwxaq52qq",
  "venue": "International Journal of Clinical Oncology",
  "versions": []
}